Evidence map›Paper›PMID 31339232›Full record

Trial reportESC heart failure2019

Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.

Rajendra K Premchand, Kamal Sharma, Sanjay Mittal, Rufino Monteiro, Imad Libbus, Jeffrey L Ardell, Douglas D Gregory, Bruce H KenKnight, Badri Amurthur, Lorenzo A DiCarlo and 1 more

Open access · goldAbstract readClinical TrialComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 2 countries.

Rajendra K PremchandKrishna Institute of Medical Sciences, Secunderabad, India.
Kamal SharmaSanjivani Super Specialty Hospitals, Ahmedabad, India.
Sanjay MittalMedanta, The Medicity, Gurugram, Haryana, India.
Rufino MonteiroVintage Hospital, Panaji, Goa, India.
Imad LibbusLivaNova USA, Inc., Houston, TX, USA.
Jeffrey L ArdellUniversity of California, Los Angeles, Los Angeles, CA, USA.
Douglas D GregoryClinical Cardiovascular Science Foundation, Boston, MA, USA.
Bruce H KenKnightLivaNova USA, Inc., Houston, TX, USA.
Badri AmurthurLivaNova USA, Inc., Houston, TX, USA.
Lorenzo A DiCarloLivaNova USA, Inc., Houston, TX, USA.
Inder S AnandUniversity of Minnesota (Emeritus), Minneapolis, MN, USA.
LivaNova (United States) · USCardiovascular Clinical Science Foundation · USKrishna Institute of Medical Sciences · INMedanta The Medicity · INSanjivani Super Speciality Hospitals · INUniversity of California, Los Angeles · USUniversity of Minnesota · USVoluntary Health Association of Goa · IN

Funding

Cyberonics Incorporated, Houston, TX, USA None
6 · The paper itself

Abstract

aimsClinical trials of new heart failure (HF) therapies administer guideline-directed medical therapy (GDMT) as background pharmacologic treatment (BPT). In the ANTHEM-HF Pilot Study, addition of autonomic regulation therapy to GDMT significantly improved left ventricular function, New York Heart Association (NYHA) class, 6 min walk distance, and quality of life in patients with HF with reduced ejection fraction (HFrEF). A post hoc analysis was performed to compare BPT in ANTHEM-HF with two other trials of novel HF therapies: the PARADIGM-HF study of sacubitril-valsartan and the SHIFT study of ivadrabine. All three studies evaluated patients with HFrEF, and the recommendations for use of GDMT were similar. A left ventricular ejection fraction ≤40% was required for entry into ANTHEM-HF and PARADIGM-HF and ≤35% for SHIFT. NYHA 2 or 3 symptoms were required for entry into ANTHEM-HF, and patients with predominantly NYHA 2 or 3 symptoms were enrolled in PARADIGM-HF and SHIFT. METHODS AND

resultsData on BPT were obtained from peer-reviewed publications and the public domain. Pearson's χ

conclusionsBackground treatment with GDMT in ANTHEM-HF compared favourably with that in two other contemporary trials of new HF therapies. The minimum period of stable GDMT required before randomization was longer, and GDMT remained unchanged for the study's duration. These findings serve to further support the potential role of autonomic regulation therapy as an adjunct to GDMT for patients with HFrEF.

Indexed as

Adrenergic beta-AntagonistsAdultAgedAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAutonomic Nervous SystemBiphenyl CompoundsCardiovascular AgentsDrug CombinationsFemaleHeart FailureHumansIvabradineMaleMiddle AgedAdrenergic beta-AntagonistsAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiphenyl CompoundsCardiovascular AgentsDrug CombinationsIvabradineMineralocorticoid Receptor Antagonistssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanAutonomic nervous systemAutonomic regulation therapyGuideline-directed medical therapyHeart failureNeuromodulationVagus nerve stimulation

Identifiers

PMID31339232
PMCPMC6816059
OpenAlexW2962899494

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.